ZAS Corporation Ltd. Partners with LABAID Diagnostics and LABAID Cancer Hospital for Employee Healthcare
ZAS Corporation Ltd. is delighted to announce the signing of a Memorandum of Understanding (MOU) with LABAID Diagnostics and LABAID […]
ZAS Corporation Ltd. is delighted to announce the signing of a Memorandum of Understanding (MOU) with LABAID Diagnostics and LABAID […]
ZAS Corporation proudly launched Uro-Vaxom, an advanced immunotherapeutic solution by OM Pharma, Switzerland, for preventing recurrent urinary tract infections (UTIs).
In collaboration with the Nephrology Department at the National Institute of Kidney Diseases & Urology (NIKDU), ZAS Corporation Ltd. hosted
ZAS Corporation proudly participated in the prestigious MOSB Congress 2024, reaffirming its dedication to advancing oncology care in Bangladesh. The
ZAS Corporation was honored to serve as the core sponsor of the 178th World Anesthesia Day celebration, organized by the
ZAS Corporation proudly marked its 19th anniversary, celebrating nearly two decades of excellence, innovation, and growth. The milestone event saw
We are thrilled to have welcomed our partners from the Morinaga Research Centre, Japan, to Bangladesh. This visit signifies a
ZAS Gyno, a division of ZAS Corporation Ltd., recently held an empowering sales conference titled “Sales Summit – Recharge &
We are delighted to announce that ZAS Corporation has successfully obtained the trademark for our brand Protimeal. Registered under trademark
We are proud to announce that ZAS Corporation Ltd. has officially secured the trademark for our brand DECA. Registered under